News Center

位置：

Honors Announcement

Group News

Media Reports

The company’s brand value ranks among the top in the pharmaceutical industry.

Category:

Honors Announcement

发布时间：2019-05-24

【概要描述】 The “2019 China Brand Value Evaluation Release and China Brand Building Summit Forum,” hosted by Xinhua News Agency, Economic Daily, the China Council for the Promotion of International Trade, the China Association for Brand Building, and the China Asset Appraisal Association, and co-organized by China Brand Magazine and other institutions, was held in Shanghai. According to the “2019 Brand Value Evaluation Release List,” a total of 49 pharmaceutical brands were featured in the healthcare sector, with Shijiazhuang Sihua Pharmaceutical Co., Ltd. ranking 16th on the list, scoring 856 points for brand strength and achieving a brand value of RMB 4.646 billion—an increase of RMB 1.179 billion over the previous year.

On May 9, the “2019 China Brand Value Evaluation Release and China Brand Building Summit Forum,” co-hosted by Xinhua News Agency, Economic Daily, the China Council for the Promotion of International Trade, the China Association for Brand Building, and the China Association of Asset Appraisers, with additional joint sponsorship from China Brand Magazine and other organizations, was held in Shanghai. According to the “2019 Brand Value Evaluation Release List,” a total of 49 pharmaceutical brands were featured in the healthcare sector, among which Shijiazhuang Sihua Pharmaceutical Co., Ltd. ranked 16th with a brand strength score of 856 and a brand value of RMB 4.646 billion. Notably, its brand value increased by RMB 1.179 billion compared with the previous year, clearly demonstrating the broad recognition the pharmaceutical market affords the Shijiazhuang Sihua brand.

This year’s release of China’s Brand Value Assessment results marks the sixth consecutive year that such an event has been held in China. The 2019 assessment covers corporate brands, product brands, regional brands, technology-innovation brands, and time-honored Chinese brands. Among these, the corporate and product brand categories are primarily targeted at industries in which China enjoys a strong industrial advantage, accounts for a substantial share of the national GDP, has a solid foundation for brand development, and meets the requisite criteria for brand evaluation. In particular, to promote traditional Chinese culture and national brands and to revitalize the prestige of time-honored brands, the latter are treated as a separate category, with independent application and evaluation processes. Following last year’s pilot initiative to conduct selective proactive evaluations, the financial sector has this year adopted fully proactive evaluation across the board and expanded the scope to other sectors, encompassing 1,293 enterprises and 598 brands.

In recent years, Shijiazhuang Sihua Pharmaceutical has adhered to the business philosophy of “integrity as the foundation, quality for the people,” using a strengthened commitment to comprehensive quality management as the driving force to build both product and corporate brands, thereby forging a quality-brand development path that is distinctly characteristic of Sihua. The company’s flagship product—large-volume parenteral solutions—has enjoyed a 50-year production history. Over the past half-century, Sihua has placed paramount importance on brand building, steadfastly upholding the principle of “quality first” while relentlessly pursuing technological advancement and scaling up production. It has taken the lead in the domestic industry by establishing a provincial-level Engineering Research Center for Large-Capacity Injectable Preparations, a National-Local Joint Laboratory for Quality Control of Chemical Injection Preparations, and a National Enterprise Technology Center. The company’s R&D investment, R&D capabilities, and patent portfolio rank among the top in the industry; key quality-control indicators for its large-volume parenteral solutions surpass the standards set by the Chinese Pharmacopoeia. Its products were recognized as one of Shijiazhuang City’s Top Ten Industrial Brands in 2017, and this year the establishment and application of a quality-control technical system for soft-packaged large-volume injectables was awarded the First Prize of the Provincial Science and Technology Progress Award.

After fifty years of brand-building, Shijiazhuang No. 4 Pharmaceutical has earned a stellar reputation in both domestic and international markets. Its soft-bag intravenous solutions account for more than 50% of the national market share, and its products have obtained six major international quality certifications and audits, including those from Australia’s TGA and the Netherlands’ IDA. The company’s reach extends across China and to 80 countries and regions, and it has been honored with numerous awards, such as the National Quality Product Award, the Provincial Famous Brand designation, and the Consumer Trusted Product award. The “Shimen” trademark of Shijiazhuang No. 4 Pharmaceutical was among the first in China’s large-volume parenteral solutions sector to be recognized as a well-known trademark. Today, the company boasts an annual production capacity of 2 billion bottles (or bags) of large-volume parenteral solutions, placing it at the forefront of the domestic industry in terms of production scale, quality standards, manufacturing technology, and brand influence. It is also ranked among the Top 100 Chinese pharmaceutical enterprises in overall strength and among the Top 10 outstanding brands for exporting chemical pharmaceutical preparations, firmly establishing itself as a key national hub for the production, R&D, and export of large-volume injectable solutions.

Chairman Qu Jiguang stated that Shijiazhuang Sihua Pharmaceutical will further accelerate its internationalization, with a strong focus on cultivating a portfolio of renowned brands that boast robust global competitiveness and high value-added. The company will continue to strengthen and expand its national pharmaceutical brand, striving to build a comprehensive, modern, and internationally oriented pharmaceutical group. Upholding its brand philosophy of becoming a world-class enterprise that produces first-rate medicines and delivers first-rate services, Sihua Pharmaceutical will actively promote the global expansion of Chinese brands, elevate the Sihua brand to the international market, and better serve human health and well-being.

Keywords:

Company-Sponsored Speech Wins Third Prize

The company’s 150 mg fluconazole tablets are the first in China to pass the consistency evaluation.

Company-Sponsored Speech Wins Third Prize

The company’s 150 mg fluconazole tablets are the first in China to pass the consistency evaluation.